May 16, 2018 | Leading financial services company Credit Suisse has committed a $250 million investment for a new life sciences venture capital fund set up by aMoon Partners last month, Reuters reported on Wednesday, citing the fund’s managing partner Dr. Yair Schindel. He and Marius Nacht, the billionaire co-founder of cybersecurity giant CheckPoint Software Technologies, are the founders of aMoon Partners. Last month, they announced that they had raised $200 million from private investors for the fund, focused on mid- to late-stage companies in the health and medical technologies field. With the latest Credit Suisse commitment, the fund is now close to meeting its target of $500 million. The average investment will be between $10 million and $40 million, Schindel said last month, with most of the investments in Israel with possible opportunities in the US, the UK, and Switzerland. The first aMoon health fund was set up in 2017, with Nacht putting up $200 million. The fund invested in 16 startups.